Australia Mrna Therapeutics Market Size & Outlook, 2024-2030
- Biotechnology
- RNA analysis
- MRNA Therapeutics Market Outlook
- RNA analysis
Global Market
Related Markets
Ask Prism AI about the mrna therapeutics market
Get cited answers from GVR research on market growth, segments, regulations and forecasts.
- Source-linked answers
- Market-specific context
- Traceable figures
Australia mrna therapeutics market highlights
- The Australia mrna therapeutics market generated a revenue of USD 215.0 million in 2023 and is expected to reach USD 691.8 million by 2030.
- The Australia market is expected to grow at a CAGR of 18.2% from 2024 to 2030.
- In terms of segment, infectious diseases was the largest revenue generating application in 2023.
- Infectious Diseases is the most lucrative application segment registering the fastest growth during the forecast period.
Mrna therapeutics market data book summary
| Market revenue in 2023 | USD 215.0 million |
| Market revenue in 2030 | USD 691.8 million |
| Growth rate | 18.2% (CAGR from 2023 to 2030) |
| Largest segment | Infectious diseases |
| Fastest growing segment | Infectious Diseases |
| Historical data | 2021 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Infectious Diseases |
| Key market players worldwide | Moderna Inc, BioNTech SE ADR, CureVac NV Ordinary Shares, Arcturus Therapeutics Holdings Inc, Sanofi SA, GSK PLC, Pfizer Inc, AstraZeneca PLC, Argos Therapeutics, ETHRIS |
Other key industry trends
- In terms of revenue, Australia accounted for 1.8% of the global mrna therapeutics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan mrna therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,786.3 million by 2030.
Rising government investments and private players in mRNA synthesis R&D are expected to boost the demand for relevant raw materials. Hence, several companies are launching innovative products and are partnering with vaccine manufacturers to provide the raw materials required for mRNA synthesis.
Owing to the rising awareness regarding mRNA vaccines in the country, companies are launching dedicated facilities for mRNA vaccine manufacturing, which is expected to boost the demand for raw materials required for mRNA synthesis.
For instance, in August 2022, Moderna, Inc. launched an mRNA vaccine manufacturing facility in Melbourne, the first in the southern hemisphere region. The facility is located at Monash, one of the largest universities in Australia, and is projected to manufacture around 100 million vaccine doses per year for influenza, COVID-19, and other diseases.
No credit card required*
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
- Turnaround
- 5–10 working days
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
MRNA Therapeutics Market Scope
MRNA Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| GSK PLC | View profile | 70,200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | www.gsk.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| BioNTech SE ADR | View profile | 6,133 | An der Goldgrube 12, Mainz, RP, Germany, D-55131 | www.biontech.de |
| Moderna Inc | View profile | 5,600 | 200 Technology Square, Cambridge, MA, United States, 02139 | www.modernatx.com |
| CureVac NV Ordinary Shares | View profile | 1,100 | Friedrich-Miescher-Strasse 15, Tubingen, BW, Germany, 72076 | www.curevac.com |
| Arcturus Therapeutics Holdings Inc | View profile | 180 | 10628 Science Center Drive, Suite 250, San Diego, CA, United States, 92121 | www.arcturusrx.com |
| Argos Therapeutics | View profile | 101-250 | Durham, North Carolina, United States, North America | www.argostherapeutics.com |
| ETHRIS | View profile | 101-250 | Planegg, Bayern, Germany, Europe | ethris.com/ |
Australia MRNA Therapeutics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to MRNA Therapeutics Market Outlook will help companies and investors design strategic landscapes.
Infectious Diseases was the largest segment with a revenue share of 100.0% in 2023.
Horizon Databook has segmented the Australia mrna therapeutics market based on infectious diseases covering the revenue growth of each sub-segment from 2021 to 2030.
Rising government investments and private players in mRNA synthesis R&D are expected to boost the demand for relevant raw materials. Hence, several companies are launching innovative products and are partnering with vaccine manufacturers to provide the raw materials required for mRNA synthesis.
Owing to the rising awareness regarding mRNA vaccines in the country, companies are launching dedicated facilities for mRNA vaccine manufacturing, which is expected to boost the demand for raw materials required for mRNA synthesis.
For instance, in August 2022, Moderna, Inc. launched an mRNA vaccine manufacturing facility in Melbourne, the first in the southern hemisphere region. The facility is located at Monash, one of the largest universities in Australia, and is projected to manufacture around 100 million vaccine doses per year for influenza, COVID-19, and other diseases.
- Australia Mrna Therapeutics Market Application Outlook (Revenue, USD Million , 2021-2030)
- Infectious Diseases
- Oncology
- Rare Genetic Diseases
- Respiratory Diseases
- Others
- Australia Mrna Therapeutics Market Type Outlook (Revenue, USD Million , 2021-2030)
- Prophylactic
- Therapeutic
- Australia Mrna Therapeutics Market End Use Outlook (Revenue, USD Million , 2021-2030)
- Hospitals & Clinics
- Research Organizations
- Others
Reasons to subscribe to MRNA Therapeutics Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of MRNA Therapeutics Market Outlook databook
- Our clientele includes a mix of MRNA Therapeutics Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia MRNA Therapeutics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Australia MRNA Therapeutics Market Outlook from 2021 to 2030, including revenue numbers, major trends, and company profiles.
Australia Mrna Therapeutics Market, 2021-2030 (US$M)
Australia mrna therapeutics market statistics, by application, 2021-2030 (US$M)
